CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX.
CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX.
复制标题
使用 cell-SELEX 选择的适体将 CD109 鉴定为潜在的鼻咽癌生物标志物
DOI：
10.18632/oncotarget.10530
复制
发表时间：
2016-08-23
期刊：
影响因子：
--
通讯作者：
Liu W
中科院分区：
文献类型：
--
作者：
Jia W;Ren C;Wang L;Zhu B;Jia W;Gao M;Zeng F;Zeng L;Xia X;Zhang X;Fu T;Li S;Du C;Jiang X;Chen Y;Tan W;Zhao Z;Liu W
鼻咽癌（Nasopharyngeal carcinoma，NPC）是中国南方及南亚地区最常见的恶性肿瘤之一。由于症状不特异，缺乏有效的生物标志物，大多数患者在晚期才被诊断出来，导致5年生存率很低。为了寻找一种新的鼻咽癌生物标志物，促进鼻咽癌的早期发现和有效治疗，我们开发了一种两步策略，包括癌细胞-指数富集配体系统进化（cell-SELEX）方法和基于适体的纯化方法。采用细胞-SELEX程序，成功筛选出4种区分鼻咽癌细胞和NP细胞分子差异的适体（S3、S5、S12和S27）。然后，使用基于适体的蛋白质纯化，膜蛋白CD 109被鉴定为适体S3的靶标。Western blot和免疫组化检测结果显示，CD 109蛋白在NPC细胞系和临床组织中呈高表达，而在NP细胞系和临床NP组织中呈低表达或不表达。我们的研究表明，CD 109通过细胞-SELEX和基于适配体的纯化策略鉴定，可能作为NPC的早期诊断和靶向治疗的潜在生物标志物。
Nasopharyngeal carcinoma (NPC) is one of the most prevailing cancers in southern China and southern Asia. Because of the nonspecific symptoms and lack of effective biomarker, most patients are diagnosed at advanced stages, resulting in poor 5-year survival rate. To identify a novel NPC biomarker facilitating early detection and effective therapy of NPC, a two-step strategy consisting of cancer cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) procedure and aptamer-based purification approach was developed. Using cell-SELEX procedure, four aptamers (S3, S5, S12 and S27) differentiating the molecular differences between NPC cells and NP cells were successfully screened. Then, using aptamer-based protein purification, membrane protein CD109 was identified as the target of aptamer S3. CD109 protein was further identified to be over-expressed in NPC cell lines and clinic tissues, but not or low in NP cell line and clinic NP tissues, detected by western blot and immunohistochemistry experiments. Our study demonstrated that CD109 identified by cell-SELEX and aptamer-based purification strategy might be used as a potential NPC biomarker for early diagnosis and targeted therapy.